29
29
41
41
42
42
38
38
50
50
64
64
66
66
49
49
28
28
1
1
2020
2011
Company (607)University (14)Research Institution (8)Hospital (1)
1 - 10 of 607
Sort by
Patent
Publication NumberJP 6633130 B2Filing StatusIssued PatentAvailabilityUnknownFiling Date2018-05-28Publication Date2020-01-22
In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phente…
Patent
Publication NumberMA 39100 B1Filing StatusIssued PatentAvailabilityUnknownFiling Date2014-12-04Publication Date2019-12-31
La présente invention concerne des compositions, des kits, des utilisations, des systèmes et des procédés pour utiliser de la naltrexone et du bupropion, ou des sels pharmaceutiquement acceptables de ces derniers, pour réduire le risque de conséquences ou d'événements cardiovasculaires indésirables, y compris des événements cardiovasculaires indésirables majeurs (mace) chez des sujets, de préférence ceux ayant un risque accru de conséquences cardiovasculaires indésirables ou mace, qui peuvent…
Patent
Publication NumberBR 112013015957 A2Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2011-12-02Publication Date2019-10-29
Compositions, uses, kits and methods for reducing binge or compulsive eating are described herein. Methods may include administering an effective combination of a dosage of a bupropion or a pharmaceutically acceptable salt thereof, and a dosage of naltrexone or a pharmaceutically acceptable salt thereof. Methods may include identifying a patient who is overweight or obese and providing an effective combination of bupropion and naltrexone to the patient. Methods may include reducing a number o…
Patent
Publication NumberEP 2523557 B1Filing StatusIssued PatentAvailabilityUnknownFiling Date2011-01-10Publication Date2019-09-25
Patent
Publication NumberMX 2019008217 AFiling StatusPatent ApplicationAvailabilityUnknownFiling Date2014-12-04Publication Date2019-09-13
The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.
Patent
Publication NumberEP 3132792 B1Filing StatusIssued PatentAvailabilityUnknownFiling Date2006-11-20Publication Date2019-09-11
Patent
Publication NumberEP 3281628 B1Filing StatusIssued PatentAvailabilityUnknownFiling Date2004-04-21Publication Date2019-09-11
Patent
Publication NumberUS 10403170Filing StatusIssued PatentAvailabilityUnknownFiling Date2017-04-19Publication Date2019-09-03
The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.
Patent
Publication NumberUS 20190262318Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2019-03-05Publication Date2019-08-29
The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
Patent
Publication NumberKR 101971218 B1Filing StatusIssued PatentAvailabilityUnknownFiling Date2007-11-08Publication Date2019-08-27
In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phente…
We found 607 documents that match your Search
Patents: 335
Clinical Trials: 18
SEC Filings: 254

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in